Introduction
In response to successful oral HIV pre-exposure prophylaxis (PrEP) clinical trial findings (Baeten et al.
2012; Grant et al.
2010; McCormack et al.
2016; Molina et al.
2015), global health authorities have endorsed the implementation of PrEP service delivery to key populations as part of a combination HIV prevention strategy (Coleman
2018; WHO
2016; WHO
2019). In many EU/EEA countries with established implementation of PrEP programming, an apparent lack of patient uptake has been observed (Coleman
2018; McCormack et al.
2016). The European Centre for Disease Prevention and Control (ECDC) estimates that 500,000 men who have sex with other men (MSM) in Europe would be likely to use PrEP, but lack access, a discrepancy dubbed the
PrEP Gap (Hayes et al.
2019). Socio-political barriers potentially contributing to the PrEP Gap include the cost of both PrEP as a drug and the related service delivery (ECDC
2019), as well as the impact of anti-lesbian, -gay, -bisexual, and -transgender (LGBT) legislation within the EU/EEA on the quality of sexual healthcare service provision (European Union Agency for Fundamental Rights [FRA]
2014; Stromdahl et al.
2015). In countries with established PrEP implementation, healthcare providers with PrEP referring and/or prescribing privileges are considered to be the
gatekeepers to patient PrEP access (Krakower and Mayer
2016), with the ability to facilitate or hinder PrEP service delivery. It is noteworthy that PrEP prescribing and/or referral privileges vary across regions; therefore, the term
healthcare provider (HCP) in this paper can be considered as an umbrella term for the variety of medical professions with PrEP-prescribing and/or referral privileges.
A growing body of research is now examining the role of HCPs in implementing PrEP into practice (Krakower and Mayer
2016; Silapaswan et al.
2017; Turner et al.
2018; Zablotska and O'Connor
2017). It appears that the prescribing of PrEP is limited to a subgroup of “innovators and early adopters” (Krakower and Mayer
2016), where HCP knowledge level of PrEP is strongly associated with past and future PrEP-prescribing practices (Krakower and Mayer
2016; Silapaswan et al.
2017; Turner et al.
2018; Zablotska and O'Connor
2017). Additionally, compared to sexual health and HIV specialists, primary care providers often demonstrate lower PrEP knowledge and a lower willingness to prescribe PrEP (Zablotska and O'Connor
2017). HCP hesitancy to prescribe PrEP has been linked to logistical barriers, such as: clinical and laboratory monitoring, time constraints, and drug cost at the patient, health system, and state levels (Krakower and Mayer
2016; Silapaswan et al.
2017; Turner et al.
2018; Zablotska and O'Connor
2017). Furthermore, it has been noted that while some HCPs with PrEP-prescribing privileges might indicate a high level of PrEP acceptability, this has not always been reflected in their prescribing practices (Krakower and Mayer
2016). The disconnect between such acceptability and actual prescribing patterns is a suspected consequence of concerned HCP attitudes around PrEP efficacy, drug toxicity, and patient adherence (Krakower and Mayer
2016; Turner et al.
2018).
There is reason to wonder if HCP discomfort with PrEP prescribing could be an extension of an overall discomfort with sexual health service provision. One of the few studies that has broached the subject in the U.S. found some telling differences between HCP groups and their comfort performing clinical activities required for PrEP implementation (Petroll et al.
2017). The authors found that compared to HIV specialists, primary care providers reported a lower frequency of
PrEP-related activities; such as initiating PrEP conversations with patients, and expressed particular discomfort with: discussing patient sexual activities, providing risk reduction counselling, and communicating an acute HIV diagnosis (Petroll et al.
2017). Furthermore, it has been argued that HCP discomfort with LGBT sexual health service provision, particularly in relation to PrEP prescribing, may be rooted in stigmatizing attitudes towards sex and sexuality (Calabrese et al.
2019; Skolnik et al.
2019; St.Vil et al.
2019). Instances of such stigma within healthcare settings have the potential to block patient access to PrEP, even when a patient may be eligible and initiating the conversation. As a result, patients who are unaware of existing and emerging sexually transmitted infection (STI) prevention strategies available to them may be left behind should they be reliant on HCPs to initiate such conversations (Adams et al.
2018; Skolnik et al.
2019).
At the time of this study, the majority of research on the role of HCPs in PrEP implementation had been carried out in North America (Krakower and Mayer
2016; Silapaswan et al.
2017; Turner et al.
2018; Zablotska and O'Connor
2017) and parts of Europe (Bil et al.
2018; Desai et al.
2016; Di Biagio et al.
2017; Gonçalves et al.
2018; Lions et al.
2019; Puro et al.
2013; Reyniers et al.
2018); however, Norway has yet to be represented in this domain. Norway is the second country in the world to provide no-cost oral PrEP to key populations through the national health scheme (ECDC
2019; Helsedirektoratet
2016). Individuals seeking PrEP must on their own, or by their general practitioner (GP), be referred to an STI clinic for a PrEP consultation and prescription (Hanlon et al.
2019; Helsedirektoratet
2016). In early 2019, approximately 1150 individuals in Norway had accessed PrEP, and the wait time for PrEP initiation within specialist care could take up to 52 weeks (Hanlon et al.
2019). While an ongoing national evaluation of PrEP implementation is monitoring the PrEP-user experience in Norway (Hanlon et al.
2019), the PrEP gatekeeper perspective has yet to be captured. The role of GPs must be examined to gain a balanced picture of PrEP implementation in Norway.
The overall aim of this study was to explore the self-reported PrEP knowledge, attitudes, and clinical experience of Norwegian GPs. Further, as sexual healthcare service provision is a prerequisite to identify eligible PrEP candidates (Nunn et al.
2017; Petroll et al.
2017), GP comfort and frequency with PrEP-related activities (Petroll et al.
2017) were also assessed. It was hypothesized that GPs who have already adopted PrEP into their clinical practice would have higher frequency of, and comfort with, PrEP-related activities.
Methods
The present study involved the design and distribution of a cross-sectional, self-administered, mixed-mode (web and mail), anonymous survey. With the exception of one survey tool targeting general public and patient samples (Jaspal et al.
2019), a formally validated instrument to measure GP attitudes towards PrEP could not be found. Survey items for the present study were adapted from previous studies (Bacon et al.
2017; Blackstock et al.
2017; Desai et al.
2016; Petroll et al.
2017; Puro et al.
2013; Reyniers et al.
2018), and modified to suit the Norwegian PrEP context. This resulted in a 56-item survey that could be completed in between 5 and 10 min. To avoid alienating GPs lacking PrEP experience, respondents were invited to participate in a survey on sexual healthcare within general practice. Friendly language was used in the invitations and surveys to encourage GP participation, regardless of their experience or knowledge with the survey content.
Study population and sample size
Norway’s capital of Oslo is the nation’s most populated city (Høydahl
2020), where HIV incidence remains highest (Blystad et al.
2019), and is host location for the evaluation of PrEP implementation project (Hanlon et al.
2019). Consequently, Oslo could be considered the PrEP epicenter of Norway, and was the rationale for restricting our study population inclusion criteria to currently practicing GPs in Oslo. At the end of 2018, there were an estimated 527 practicing GPs in Oslo (Gaardsrud
2019). To calculate our target sample size in STATA (StataCorp
2017), we referred to a previous study of PrEP implementation among Belgian physicians (Reyniers et al.
2018) to base our assumptions of proportion/prevalence of GP PrEP adoption, and its association with PrEP knowledge and attitudes. A sample size of 112 Oslo GPs was required to achieve 80% power (at 5% significance level), while a sample of 148 Oslo GPs would achieve 90% power. A total of 117/527 Oslo GPs responded to our survey, resulting in a 22% response rate.
Data collection
Study invitations and surveys were distributed using a sequential web-mail recruitment method. The web survey invitation and subsequent reminders were first emailed to the head physician of each subdivision within Oslo, who then forwarded the survey to their respective GP listservs. The first web survey invite took place in November 2019, followed by two email reminders with a web survey link at 3-week intervals. Postal survey distribution took place in late January 2020 and contained, per GP within each clinic: one survey invitation letter, one survey, and one pre-stamped return envelope. Web and mail data collection closed in February 2020. Between the two survey modes, 44 respondents submitted responses to the web survey, while 73 respondents completed and returned the postal survey.
Covariates
Personal GP characteristics included demographic variables (gender identity, sexual orientation, country of birth), as well as details regarding clinical experience (location of medical exam, years of experience, number of GP colleagues in current practice setting). Respondents were provided the option of ‘prefer to not answer’ to survey items that could be perceived as too sensitive. Patient demographics were also captured by asking respondents to estimate the approximate number of LGBT patients (0, < 5, 5–10, 10+, do not know), and proportion of patients belonging to an ethnic minority background (< 25%, 25–50%, 50%+, do not know) currently on their list.
Exposure variables
One caveat to a GP referring eligible patients to a PrEP clinic is having completed a recent sexual history and STI screening. Survey items regarding GP self-reported comfort providing PrEP-related activities to patients of various demographics were measured using a five-point Likert scale; with the most negative response options (very uncomfortable, very difficult) coded as ‘1’, ascending to the most positive response options (very comfortable, very easy) coded as ‘5’. Five-point Likert scales were also used to measure the nine GP self-reported PrEP attitudes (strongly disagree to strongly agree). Selected Likert-scale survey items were combined to create unique composite scales that would act as continuous exposure measures in the data analysis. This resulted in four composite scales: GP comfort in discussing sex with LGBT identifying patients (four items, Cronbach’s α = 0.81); GP comfort in discussing sex with patients from ethnic minority backgrounds (three items, Cronbach’s α = 0.77); GP accepting attitudes towards PrEP (five items, Cronbach’s α = 0.74); and GP concerned attitudes towards PrEP (four items, Cronbach’s α = 0.67). Accepting PrEP attitudes included statements such as: ‘PrEP should remain free of cost’ and ‘It is reasonable to schedule control consultations every 3 months to healthy patients’. Concerned PrEP attitudes included ‘PrEP could lead to an increase in patient HIV risk behaviours’ and ‘PrEP isn’t necessary — condoms are already an effective HIV prevention strategy’.
In addition to the four composite exposure scales, two independent exposure variables were included in the multivariate analysis. GP self-reported PrEP knowledge was measured by one survey item with a six-point Likert scale (never heard of PrEP to excellent PrEP knowledge level) and treated as a continuous variable. As a proxy exposure to measure a GP's frequency of carrying out PrEP-related activities, we used the one categorical survey item capturing the number of syphilis tests provided by a GP in the last 3-month period (0, < 5, 5–10, 10+).
Outcome variable
The outcome variable of interest was GP
PrEP adoption (Krakower and Mayer
2016; Turner et al.
2018). Survey respondents were asked if they had
ever provided a patient with a referral or prescription for HIV PrEP. Respondents who answered ‘yes’ were classified as
PrEP-adopters, while those who answered ‘no’ were classified as
PrEP non-adopters.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.